Additionally, other CDK9i including Atuveciclib, BAY 1251152, and LDC000067 were evaluated for their synergistic effects with MEKi/ERKi on various KRAS‐mutant cancer cell lines, with CI values less than 1 (Figure 4D). Here, KRAS is linked to cancer.